SUBSCRIBE
SUBSCRIBE
Kate Goodwin

Kate Goodwin

Contributing Writer | News & Features

Kate Goodwin hails from a background primarily in marketing. A passion for health sciences and writing led her to the biopharma news world, and she’s never looked back. She’s been writing for BioSpace for more than two years with a focus on cutting edge research, Alzheimer’s disease and pediatrics. Her free time is filled by her husband, children, Beagles, books, crochet and creative writing. She can be reached at kate.goodwin@biospace.com.

Pictured: Astellas sign with logo/yu_photo/Adobe S
Deals
Astellas to Buy Iveric Bio for $5.9B in Age-Related Blindness Play
Japanese biopharma scoops up Iveric’s investigational drug for age-related blindness disease. The drug, which trails Apellis’ Syfovre, is awaiting FDA approval with a decision expected by August.
May 1, 2023
 · 
2 min read
 · 
Kate Goodwin
Pictured: AbbVie sign on a building/courtesy of Ad
Business
Humira Sales Down 25% as AbbVie Cuts Two Programs
As Humira global revenues fall 25%, AbbVie looks to Rinvoq and Skyrizi to fill in the gap. The company also announced it is cutting cystic fibrosis and Crohn’s disease candidates.
April 28, 2023
 · 
2 min read
 · 
Kate Goodwin
Pictured: Blue and white Sanofi sign on building/R
Drug Development
Sanofi Cleans House, Cuts Assets from Principia and Ablynx Buyouts
The French pharma drops another BTK inhibitor program from Principia and an anti-TNFa from Ablynx.
April 27, 2023
 · 
2 min read
 · 
Kate Goodwin
PictureDesignSwiss / Shutterstock
Business
Biogen Bets on Anticipated Approvals Amidst Pipeline Reprioritization
During its Q1 earnings call Tuesday, Biogen announced a handful of program pauses and cuts and touted the potential of anticipated approvals.
April 26, 2023
 · 
4 min read
 · 
Kate Goodwin
Bodo Marks/picture alliance via Getty
Drug Development
Ionis and AstraZeneca Seek to Challenge Alnylam with New ATTR Data
Eplontersen halted ATTRv-PN disease progression and improved quality of life through 66 weeks. The drug has a PDUFA date of Dec. 22, 2023.
April 24, 2023
 · 
2 min read
 · 
Kate Goodwin
Vaccines bottles lined up_Mdisk/Adobe Stock
AACR Highlights the Potential of Cancer Vaccines
Cancer vaccines enjoyed a moment in the spotlight this week as Moderna, Merck, Nykode Therapeutics and Transgene shared promising updates at AACR and beyond.
April 21, 2023
 · 
5 min read
 · 
Kate Goodwin
Pictured: AbbVie sign on a building/courtesy of Ad
Drug Development
AbbVie’s Migraine Drug Scores Another Phase III Win
AbbVie shared more positive results for its migraine prevention drug, Qulipta, just three days after FDA approval to expand its label.
April 21, 2023
 · 
2 min read
 · 
Kate Goodwin
Drug Development
BeiGene’s Tislelizumab Garners Another Phase III Win but Still Awaits Approval in US
The checkpoint inhibitor is approved for several cancers in China, but after an indefinite FDA delay last summer, BeiGene’s partner Novartis still awaits its first U.S. approval.
April 20, 2023
 · 
2 min read
 · 
Kate Goodwin
Courtesy of JHVEPhoto/GettyImages
FDA
FDA Approves First Drug for Agitation in Alzheimer’s Dementia: Update
Thursday, the FDA greenlit Ostuka and Lundbeck’s Rexulti as the first treatment in the U.S. for agitation associated with dementia due to Alzheimer’s disease.
April 17, 2023
 · 
3 min read
 · 
Kate Goodwin
Pictured: A doctor holds a chest x-ray/courtesy of
Business
Aer Therapeutics Raises $36M for Novel Approach to COPD
Aer’s inhaled formulation targets the mucus plugs obstructing COPD patients’ airways.
April 14, 2023
 · 
3 min read
 · 
Kate Goodwin
Pictured: micrograph of uterine biopsy/iStock
Drug Development
With Positive Phase III Data, Junshi’s PARP Inhibitor could Challenge Lynparza
Junshi Biosciences announced Tuesday that its ovarian cancer candidate, senaparib, met the primary endpoint in a Phase III interim analysis.
April 12, 2023
 · 
2 min read
 · 
Kate Goodwin
Pictured: Illustration of a motor neuron being deg
Drug Development
AI Therapeutics Posts First Clinical Data for New ALS Mechanism
Phase IIa data showed AI Therapeutics’ ALS candidate increased expression of a target engagement biomarker and led to a 73% reduction in a toxic protein aggregate.
April 6, 2023
 · 
2 min read
 · 
Kate Goodwin
Pictured: Exelixis headquarters/Company courtesy
Policy
Hedge Fund Wages Proxy Battle with Exelixis Over R&D
Farallon Capital Management is waging a proxy battle with Exelixis over R&D spending. The hedge fund issued a letter to the company’s board of directors on Wednesday.
April 6, 2023
 · 
3 min read
 · 
Kate Goodwin
Pictured: Two business people shaking hands / iSto
Business
Proxygen Snags Third Big Pharma Partner in Deal Valued at $2.55B
Proxygen added Merck to its partner roster on Wednesday, garnering an undisclosed upfront payment plus a potential $2.55 billion in milestones.
April 5, 2023
 · 
2 min read
 · 
Kate Goodwin
Pictured: BioNTech flags fly in the wind/Andreas A
Business
BioNTech Adds Two ADCs in Second Deal in as Many Months
BioNTech will pay Shanghai-based Duality Biologics $170 million upfront for rights to two of its topoisomerase-1 inhibitor-based antibody drug conjugates.
April 3, 2023
 · 
2 min read
 · 
Kate Goodwin
Load More